This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Formulary Decisions and Health Economics

William M. Glazer, M.D.

Published: May 1, 1998

Article Abstract

Because of increasing concerns about health care costs, physicians must consider the cost-effectivenessof a treatment strategy, as well as its efficacy and safety. The question of whether the greaterexpense of a newer drug is justified over the cost of a generic drug deserves a comprehensive evaluation.The determination of effectiveness and tolerability of the newer antipsychotics should be expandedto include quality-of-life issues, reintegration of the patient into the community, resource utilization,and medical costs. There are clear indications that patients who take atypical antipsychoticsutilize fewer medical resources than patients who take typical antipsychotics; however, the positiveoutcomes of the newer drugs must be translated into cost benefits if formularies are to be intelligentlycontrolled.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 59

Quick Links: